Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
about
A conjugate of octamer-binding transcription factor 4 and toll-like receptor 7 agonist prevents the growth and metastasis of testis embryonic carcinomaThe impact of patent eligibility on biotech patents: A flow chart for determining patent eligibility and an immune therapy case studyXenogene vaccination in the therapy of cancer.Lentiviral vectors in cancer immunotherapy.Rationale for combining immunotherapy with chemotherapy.
P2860
Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
@en
Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
@nl
type
label
Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
@en
Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
@nl
prefLabel
Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
@en
Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
@nl
P2860
P1476
Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
@en
P2093
Erin E Roesch
Nancy A Dawson
P2860
P304
P356
10.1517/14712598.2014.896897
P407
P577
2014-03-12T00:00:00Z